heart%20failure%20-%20chronic
HEART FAILURE - CHRONIC
Heart failure is a clinical syndrome due to a structural or functional cardiac disorder that impairs the ability of the ventricle to fill with or eject blood in order to deliver oxygen at a rate commensurate with the requirements of the metabolizing tissues.
Symptoms are caused by ventricular dysfunction secondary to abnormalities of the myocardium, pericardium, endocardium, valves, heart rhythm and conduction.
Chronic heart failure is a state where patient's signs and symptoms have been unchanged (stable) for at least a month but may decompensate suddenly or slowly when stable chronic heart failure deteriorates leading to hospitalization.

Heart Failure - Chronic Drug Information

Drug Information

Indication: Symptomatic treatment of chronic stable angina pectoris in CAD adults w/ normal sinus rhythm & heart rate&...

Indication: Substitution treatment of essential HTN &/or stable CAD in patients already controlled w/ perindopril &...

Indication: HTN. Stable CAD: Risk reduction of cardiac events in patients w/ history of MI &/or revascularisation. 5 m...

Indication: Essential HTN in adults.

Indication: HTN. Reduce risk of stroke in patients w/ HTN & left ventricular hypertrophy (LVH). Diabetic nephropathy w...

Indication: HTN for patients in whom combination therapy is appropriate. Reduce the risk of stroke in patients w/ HTN &...

Indication: HTN for patients in whom combination therapy is appropriate. Reduce the risk of stroke in patients w/ HTN &...

Indication: Essential HTN when BP is inadequately controlled by monotherapy w/ telmisartan.

Indication: 1st line treatment of HTN & myocardial ischemia whether due to fixed obstruction (stable angina) &/or ...

1  /  18
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 12 Sep 2020
Early initiation of rhythm-control therapy led to a significantly reduced risk of major adverse cardiovascular (CV) outcomes compared with usual care (typically rate control) in patients with newly diagnosed atrial fibrillation (AF) at risk of stroke, reveals the EAST-AFNET 4* trial presented at ESC 2020.
Audrey Abella, 16 Sep 2020
The final results of EVAPORATE* reinforce the plaque-regressing potential of icosapent ethyl (IPE) in patients on statins for elevated triglycerides.